Publications
Selected publications
- Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1 (Journal article - 2022)
- An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars (Journal article - 2022)
- Exposure of the Basophilic Cell Line KU812 to Liposomes Reveals Activation Profiles Associated with Potential Anaphylactic Responses Linked to Physico-Chemical Characteristics (Journal article - 2022)
- Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19 (Journal article - 2021)
- Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier (Journal article - 2021)
- Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free, anticoagulant activity (Journal article - 2020)
- Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems (Journal article - 2018)
2024
Nano(bio)Materials Do Not Affect Macrophage Phenotype-A Study Conducted by the REFINE Project.
David, C. A. W., Vermeulen, J. P., Gioria, S., Vandebriel, R. J., & Liptrott, N. J. (2024). Nano(bio)Materials Do Not Affect Macrophage Phenotype-A Study Conducted by the REFINE Project.. International journal of molecular sciences, 25(10), 5491. doi:10.3390/ijms25105491
In vitro evaluation of physicochemical-dependent effects of polymeric nanoparticles on their cellular uptake and co-localization using pulmonary calu-3 cell lines.
Osman, N., Curley, P., Box, H., Liptrott, N., Sexton, D., & Saleem, I. (2024). <i>In vitro</i> evaluation of physicochemical-dependent effects of polymeric nanoparticles on their cellular uptake and co-localization using pulmonary calu-3 cell lines.. Drug development and industrial pharmacy, 50(4), 376-386. doi:10.1080/03639045.2024.2332889
2023
Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.
Liu, C., Hern, F. Y., Shakil, A., Temburnikar, K., Chambon, P., Liptrott, N., . . . Rannard, S. P. (2023). Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.. Journal of materials chemistry. B, 11(48), 11532-11543. doi:10.1039/d3tb02268d
Umbilical cord mesenchymal stromal cell-derived extracellular vesicles lack the potency to immunomodulate human monocyte-derived macrophages in vitro.
da Silva, T. B., Rendra, E., David, C. A. W., Bieback, K., Cross, M. J., Wilm, B., . . . Murray, P. (2023). Umbilical cord mesenchymal stromal cell-derived extracellular vesicles lack the potency to immunomodulate human monocyte-derived macrophages in vitro.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 167, 115624. doi:10.1016/j.biopha.2023.115624
Late Breaking Abstract - Age and vitamin D influence airway epithelial cells response to SARS-CoV-2 infection
Sposito, F., Pennington, S., David, C., Duggan, J., Northey, S., Biagini, G., . . . Hedrich, C. (2023). Late Breaking Abstract - Age and vitamin D influence airway epithelial cells response to SARS-CoV-2 infection. In Airway cell biology and immunopathology (pp. OA4962). European Respiratory Society. doi:10.1183/13993003.congress-2023.oa4962
Intravenous Administration of Human Umbilical Cord Mesenchymal Stromal Cells Leads to an Inflammatory Response in the Lung.
Hernandez Pichardo, A., Wilm, B., Liptrott, N. J., & Murray, P. (2023). Intravenous Administration of Human Umbilical Cord Mesenchymal Stromal Cells Leads to an Inflammatory Response in the Lung.. Stem cells international, 2023, 7397819. doi:10.1155/2023/7397819
Age differential CD13 and interferon expression in airway epithelia affect SARS-CoV-2 infection - effects of vitamin D.
Sposito, F., Pennington, S. H., A W David, C., Duggan, J., Northey, S., Biagini, G., . . . Hedrich, C. M. (2023). Age differential CD13 and interferon expression in airway epithelia affect SARS-CoV-2 infection - effects of vitamin D.. Mucosal immunology, S1933-0219(23)00064-8. doi:10.1016/j.mucimm.2023.08.002
Application of KU812 cells for assessing complement activation related effects by nano(bio)materials.
David, C., de la Fonteyne-Blankestijn, L., Vermeulen, J., Plant-Hately, A., Vandebriel, R., & Liptrott, N. (2023). Application of KU812 cells for assessing complement activation related effects by nano(bio)materials. Biomedicine and Pharmacotherapy. doi:10.1016/j.biopha.2023.114841
Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.
Curley, P., Hobson, J. J., Liptrott, N. J., Makarov, E., Al-Khouja, A., Tatham, L., . . . Owen, A. (2023). Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.. Pharmaceutics, 15(7), 1835. doi:10.3390/pharmaceutics15071835
Fate of intravenously administered umbilical cord mesenchymal stromal cells and interactions with the host's immune system
Amadeo, F., Hanson, V., Liptrott, N. J., Wilm, B., Murray, P., & Taylor, A. (2023). Fate of intravenously administered umbilical cord mesenchymal stromal cells and interactions with the host's immune system. BIOMEDICINE & PHARMACOTHERAPY, 159. doi:10.1016/j.biopha.2022.114191
2022
Exposure of the Basophilic Cell Line KU812 to Liposomes Reveals Activation Profiles Associated with Potential Anaphylactic Responses Linked to Physico-Chemical Characteristics
Plant-Hately, A. J., Eryilmaz, B., David, C. A. W., Brain, D. E., Heaton, B. J., Perrie, Y., & Liptrott, N. J. (2022). Exposure of the Basophilic Cell Line KU812 to Liposomes Reveals Activation Profiles Associated with Potential Anaphylactic Responses Linked to Physico-Chemical Characteristics. PHARMACEUTICS, 14(11). doi:10.3390/pharmaceutics14112470
Intravenous administration of human umbilical cord mesenchymal stromal cells leads to an inflammatory response in the lung
An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars
Vandebriel, R. J., David, C. A. W., Vermeulen, J. P., & Liptrott, N. J. (2022). An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars. DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 12(9), 2225-2242. doi:10.1007/s13346-022-01206-6
Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances
Minnema, J., Borgos, S. E. F., Liptrott, N., Vandebriel, R., & Delmaar, C. (2022). Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances. DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 12(9), 2132-2144. doi:10.1007/s13346-022-01159-w
Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants
Shakil, A., Hern, F. Y., Liu, C., Temburnikar, K., Chambon, P., Liptrott, N., . . . Rannard, S. P. (2022). Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants. JOURNAL OF MATERIALS CHEMISTRY B, 10(23), 4395-4404. doi:10.1039/d2tb00825d
Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1
Heaton, B. J., Jensen, R. L., Line, J., David, C. A. W., Brain, D. E., Chadwick, A. E., & Liptrott, N. J. (2022). Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1. BIOMEDICINE & PHARMACOTHERAPY, 150. doi:10.1016/j.biopha.2022.112999
Effects of nano-enabled chemotherapeutic delivery systems upon tissue based immune cells.
Plant-Hately, A., Eryilaz, B., Perrie, Y., & Liptrott, N. (2022). Effects of nano-enabled chemotherapeutic delivery systems upon tissue based immune cells.. Poster session presented at the meeting of British Toxicology Society 2022. Newcastle, UK.
Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies
Amadeo, F., Plagge, A., Chacko, A., Wilm, B., Hanson, V., Liptrott, N., . . . Taylor, A. (2022). Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 49(3), 796-808. doi:10.1007/s00259-021-05439-4
PBPK Modelling for Intratumoral Biodistribution of Magnetic Iron Oxide Nanoparticles
Mohamed, D. A., Howarth, A., Abasolo, I., Montanha, M., Llaguno, M., Southern, P., . . . Liptrott, N. (2022, April 2). PBPK Modelling for Intratumoral Biodistribution of Magnetic Iron Oxide Nanoparticles. In World Congress on Recent Advances in Nanotechnology. Avestia Publishing. doi:10.11159/nddte22.140
2021
Assessment of cell-mediated effects, related to infusion reactions to nano-enabled chemotherapeutic delivery systems.
Plant-Hately, A., Eryilaz, B., Perrie, Y., & Liptrott, N. (2021). Assessment of cell-mediated effects, related to infusion reactions to nano-enabled chemotherapeutic delivery systems.. Poster session presented at the meeting of Liverpool Cancer Research Institute, Scientific Symposium. Liverpool.
Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19
Brain, D., Plant-Hately, A., Heaton, B., Arshad, U., David, C., Hedrich, C., . . . Liptrott, N. J. (2021). Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. ADVANCED DRUG DELIVERY REVIEWS, 178. doi:10.1016/j.addr.2021.113848
Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation
Halamoda-Kenzaoui, B., Vandebriel, R. J., Howarth, A., Siccardi, M., David, C. A. W., Liptrott, N. J., . . . Caputo, F. (2021). Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation. JOURNAL OF CONTROLLED RELEASE, 336, 192-206. doi:10.1016/j.jconrel.2021.06.016
Assessment of changes in autophagic vesicles in human immune cell lines exposed to nano particles
David, C. A. W., del Castillo Busto, M. E., Cuello-Nunez, S., Goenaga-Infante, H., Barrow, M., Fernig, D. G., . . . Liptrott, N. J. (2021). Assessment of changes in autophagic vesicles in human immune cell lines exposed to nano particles. CELL AND BIOSCIENCE, 11(1). doi:10.1186/s13578-021-00648-8
AUTOSTERE: Systematic Search for Scaffold Replacement Opportunities within Structural Databases
Heal, J. R., Sheridan, J. M., Kulkarni, M., Liptrott, N., Egan, D., Khoo, S., . . . Hamilton, W. D. O. (2021). AUTOSTERE: Systematic Search for Scaffold Replacement Opportunities within Structural Databases. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 61(4), 1778-1788. doi:10.1021/acs.jcim.0c01261
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection
Hobson, J. J., Savage, A. C., Dwyer, A., Unsworth, C., Massam, J., Arshad, U., . . . Rannard, S. (n.d.). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. Nanoscale. doi:10.1039/d1nr00309g
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis
Rajoli, R. K. R., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2021). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 2078-2088. doi:10.1111/bcp.14619
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection
Hobson, J., Savage, A., Dwyer, A., Unsworth, C., Arshad, U., Pertinez, H., . . . Rannard, S. (2021). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. doi:10.26434/chemrxiv.13587035
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection
Hobson, J., Savage, A., Dwyer, A., Unsworth, C., Arshad, U., Pertinez, H., . . . Rannard, S. (2021). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. doi:10.26434/chemrxiv.13587035.v1
Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier
Avila, Y. I., Chandler, M., Cedrone, E., Newton, H. S., Richardson, M., Xu, J., . . . Dobrovolskaia, M. A. (2021). Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier. MOLECULES, 26(3). doi:10.3390/molecules26030652
2020
Involvement of pattern recognition receptors in the immune response to lipid-based nanoparticles - a comparison of basophil and mast cell lines.
Plant-Hately, A., Eryilaz, B., Perrie, Y., & Liptrott, N. (2020). Involvement of pattern recognition receptors in the immune response to lipid-based nanoparticles - a comparison of basophil and mast cell lines.. Poster session presented at the meeting of British Pharmacological Society. Online.
In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells
David, C. A. W., Barrow, M., Murray, P., Rosseinsky, M. J., Owen, A., & Liptrott, N. J. (n.d.). In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells. International Journal of Molecular Sciences, 21(16), 5610. doi:10.3390/ijms21165610
Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free, anticoagulant activity
Hobson, J. J., Rannard, S. P., Owen, A., & Liptrott, N. J. (2020). Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free, anticoagulant activity. Nanomedicine. doi:10.2217/nnm-2019-0447
Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909
Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.
Rajoli, R. K., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2020). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.. medRxiv : the preprint server for health sciences. doi:10.1101/2020.05.01.20087130
Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K. R., Curley, P., . . . Owen, A. (2020). Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics. doi:10.1101/2020.04.16.20068379
Critical considerations for targeting colorectal liver metastases with nanotechnology
Arshad, U., Sutton, P. A., Ashford, M. B., Treacher, K. E., Liptrott, N. J., Rannard, S. P., . . . Owen, A. (2020). Critical considerations for targeting colorectal liver metastases with nanotechnology. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 12(2). doi:10.1002/wnan.1588
2019
Recognition of liposomal nanoparticles by basophils – linking their activation to the induction of complement activation related pseudoallergy. All have the same author lists, by Plant-Hately, Alexander
Plant-Hately, A., Eryilaz, B., Perrie, Y., & Liptrott, N. (2019). Recognition of liposomal nanoparticles by basophils – linking their activation to the induction of complement activation related pseudoallergy. All have the same author lists, by Plant-Hately, Alexander. Poster session presented at the meeting of British Society of Immunology.
Immunotoxicity Considerations for Next Generation Cancer Nanomedicines
Hannon, G., Lysaght, J., Liptrott, N. J., & Prina-Mello, A. (2019). Immunotoxicity Considerations for Next Generation Cancer Nanomedicines. ADVANCED SCIENCE, 6(19). doi:10.1002/advs.201900133
Bridging communities in the field of nanomedicine
Halamoda-Kenzaoui, B., Baconnier, S., Bastogne, T., Bazile, D., Boisseau, P., Borchard, G., . . . Bremer-Hoffmann, S. (2019). Bridging communities in the field of nanomedicine. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 106, 187-196. doi:10.1016/j.yrtph.2019.04.011
Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?
Tatham, L. M., Liptrott, N. J., Rannard, S. P., & Owen, A. (2019). Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?. MOLECULES, 24(15). doi:10.3390/molecules24152685
Initial assessment of the suitability of Galleria mellonella for the study of long acting formulations.
Neary, M., Sharp, J., Curley, P., Whiteford, S., Liptrott, N., & Owen, A. (2019). Initial assessment of the suitability of Galleria mellonella for the study of long acting formulations.. In Early Career Researcher Meeting British Society of Nanomedicine. Glasgow.
Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies
Urban, P., Liptrott, N. J., & Bremer, S. (2019). Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 11(3). doi:10.1002/wnan.1546
2018
Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach.
Chan, C. Y. S., Roberts, O., Rajoli, R. K. R., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2018). Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. DRUG METABOLISM AND PHARMACOKINETICS, 33(4), 179-187. doi:10.1016/j.dmpk.2018.01.004
Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems
Liptrott, N. J., Giardiello, M., McDonald, T. O., Rannard, S. P., & Owen, A. (2018). Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems. JOURNAL OF NANOBIOTECHNOLOGY, 16. doi:10.1186/s12951-018-0349-y
Advances in nanomedicine drug delivery applications for HIV therapy
Curley, P., Liptrott, N. J., & Owen, A. (2018). Advances in nanomedicine drug delivery applications for HIV therapy. FUTURE SCIENCE OA, 4(1). doi:10.4155/fsoa-2017-0069
Investigation of KU-812 cells as an in vitro model for basophil activation and assessment of complement related interactions.
David, C., Plant-Hately, A. J., & Liptrott, N. J. (2018). Investigation of KU-812 cells as an in vitro model for basophil activation and assessment of complement related interactions.. Poster session presented at the meeting of CLINAM. Basel.
Potential for immune modulation by inhibition of autophagic processes.
David, C., Owen, A., & Liptrott, N. J. (2018). Potential for immune modulation by inhibition of autophagic processes.. Poster session presented at the meeting of Nanomedicine's Early Career Researchers Meeting. London.
2017
Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
Chan, C., Martin, P., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2017). Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. PHARMACOLOGY RESEARCH & PERSPECTIVES, 5(5). doi:10.1002/prp2.359
In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line
Curley, P., Giardiello, M., Liptrott, N. J., Dickens, D., Moss, D. M., Hobson, J. J., . . . Owen, A. (2017). In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. Journal of Interdisciplinary Nanomedicine, 2(3), 157-169. doi:10.1002/jin2.32
Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system
Liptrott, N. J., Giardiello, M., McDonald, T. O., Rannard, S. P., & Owen, A. (2017). Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system. NANOMEDICINE, 12(17), 2043-2054. doi:10.2217/nnm-2017-0095
Functionalized superparamagnetic iron oxide nanoparticles provide highly efficient iron-labeling in macrophages for magnetic resonance-based detection in vivo.
Sharkey, J., Starkey Lewis, P. J., Barrow, M., Alwahsh, S. M., Noble, J., Livingstone, E., . . . Park, B. K. (2017). Functionalized superparamagnetic iron oxide nanoparticles provide highly efficient iron-labeling in macrophages for magnetic resonance-based detection in vivo.. Cytotherapy, 19(4), 555-569. doi:10.1016/j.jcyt.2017.01.003
Modulation of inflammasome activation through manipulation of autophagic processes in primary human immune cells.
David, C., Ahmed, F., Owen, A., & Liptrott, N. (2017). Modulation of inflammasome activation through manipulation of autophagic processes in primary human immune cells.. Journal of Interdisciplinary Nanomedicine.
Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines
Rosslein, M., Liptrott, N. J., Owen, A., Boisseau, P., Wick, P., & Herrmann, I. K. (2017). Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines. NANOTOXICOLOGY, 11(2), 147-149. doi:10.1080/17435390.2017.1279361
Assessment of the potential interactions of hyperbranched polydendrons with immunological and haematological systems.
David, C., Giardiello, M., Rannard, S. P., Owen, A., & Liptrott, N. J. (2017). Assessment of the potential interactions of hyperbranched polydendrons with immunological and haematological systems.. Poster session presented at the meeting of BSNM Early Career Researchers' Meeting. Belfast.
Efavirenz Is Predicted To Accumulate in Brain Tissue: an <i>In Silico</i>, <i>In Vitro</i>, and <i>In Vivo</i> Investigation
Curley, P., Rajoli, R. K. R., Moss, D. M., Liptrott, N. J., Letendre, S., Owen, A., & Siccardi, M. (2017). Efavirenz Is Predicted To Accumulate in Brain Tissue: an <i>In Silico</i>, <i>In Vitro</i>, and <i>In Vivo</i> Investigation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi:10.1128/AAC.01841-16
USE OF MRNA SUPPRESSION TO ESTIMATE CYP3A4 PROTEIN DEGRADATION RATE CONSTANT IN PRIMARY HUMAN HEPATOCYTES
Chan, C. Y., Roberts, O., Hassan, N., Liptrott, N., Siccardi, M., Almond, L., & Owen, A. (2017). USE OF MRNA SUPPRESSION TO ESTIMATE CYP3A4 PROTEIN DEGRADATION RATE CONSTANT IN PRIMARY HUMAN HEPATOCYTES. In DRUG METABOLISM AND PHARMACOKINETICS Vol. 32 (pp. S109). doi:10.1016/j.dmpk.2016.10.099
2016
Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies
Giardiello, M., Liptrott, M. J., McDonald, T. O., Moss, D., Siccardi, M., Martin, P., . . . Owen, A. (2016). Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications, 7. doi:10.1038/ncomms13184
Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.
Siccardi, M., Martin, P., Smith, D., Curley, P., McDonald, T., Giardiello, M., . . . Owen, A. (2016). Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.. Journal of interdisciplinary nanomedicine, 1(3), 110-123. doi:10.1002/jin2.21
Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV-infected individuals with lymphoma
McFaul, K., Liptrott, N., Cox, A., Martin, P., Egan, D., Owen, A., . . . Boffito, M. (2016). Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV-infected individuals with lymphoma. HIV CLINICAL TRIALS, 17(5), 197-203. doi:10.1080/15284336.2016.1210719
Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches
David, C. A. W., Owen, A., & Liptrott, N. J. (2016). Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches. NANOMEDICINE, 11(11), 1447-1464. doi:10.2217/nnm-2016-0017
Handbook of Immunological Properties of Engineered Nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (n.d.). Handbook of Immunological Properties of Engineered Nanomaterials. WORLD SCIENTIFIC. doi:10.1142/9677
Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles
Silva, A. H., Locatelli, C., Filippin-Monteiro, F. B., Martin, P., Liptrott, N. J., Zanetti-Ramos, B. G., . . . Creczynski-Pasa, T. B. (2016). Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. TOXICOLOGY LETTERS, 246, 17-27. doi:10.1016/j.toxlet.2016.01.018
Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery
Liptrott, N. J., Curley, P., Tatham, L. M., & Owen, A. (2016). Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery. In Frontiers in Nanobiomedical Research (pp. 205-239). WORLD SCIENTIFIC. doi:10.1142/9789813140479_0009
Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.
David, C., Owen, A., & Liptrott, N. J. (2016). Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.. Poster session presented at the meeting of University of Liverpool ITM Research Day. Liverpool.
2015
The Application of Nanotechnology to Drug Delivery in Medicine
McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Rannard, S., & Owen, A. (2015). The Application of Nanotechnology to Drug Delivery in Medicine. In Nanoengineering (pp. 173-223). Elsevier. doi:10.1016/b978-0-444-62747-6.00007-5
Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions
Liptrott, N. J., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2015). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. NANOMEDICINE, 10(9), 1407-1421. doi:10.2217/NNM.14.77
Chapter 2.2 The Application of Nanotechnology to Drug Delivery in Medicine
McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Rannard, S., & Owen, A. (2015). Chapter 2.2 The Application of Nanotechnology to Drug Delivery in Medicine. In Nanoengineering (pp. 173-223). Elsevier. doi:10.1016/b978-0-444-62747-6.00007-5
Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.
David, C., Owen, A., & Liptrott, N. J. (2015). Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.. Poster session presented at the meeting of European Nanomedicine Meeting. Grenoble.
Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter
Moss, D. M., Liptrott, N. J., Siccardi, M., & Owen, A. (2015). Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. FRONTIERS IN PHARMACOLOGY, 6. doi:10.3389/fphar.2015.00078
Optimisation of higher throughput assays for assessing the impact of nanomaterials on autophagy.
David, C., Liptrott, N. J., & Owen, A. (2015). Optimisation of higher throughput assays for assessing the impact of nanomaterials on autophagy.. Poster session presented at the meeting of University of Liverpool Poster Day. Liverpool.
Optimisation of methodology to assess the impact of nanomaterials on autophagy.
David, C., Owen, A., & Liptrott, N. J. (2015). Optimisation of methodology to assess the impact of nanomaterials on autophagy.. Poster session presented at the meeting of BSNM Young Researcher Meeting. Liverpool.
Utility of kinetic measurement of oxidative stress in nanotoxicological assay development.
David, C., Raymant, M. L., Owen, A., & Liptrott, N. J. (2015). Utility of kinetic measurement of oxidative stress in nanotoxicological assay development.. Poster session presented at the meeting of Nanotechnology in Medicine. Manchester.
2014
Partial mitigation of gold nanoparticle-interactions with human lymphocytes by surface functionalization with a 'mixed-matrix'
Liptrott, N. J., Kendall, E., Nieves, D. J., Farrell, J., Rannard, S., Fernig, D. G., & Owen, A. (2014). Partial mitigation of gold nanoparticle-interactions with human lymphocytes by surface functionalization with a 'mixed-matrix'. Nanomedicine, 9(16), 2467-2479. doi:10.2217/nnm.14.38
Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation
McDonald, T. O., Giardiello, M., Martin, P., Siccardi, M., Liptrott, N. J., Roberts, P., . . . Owen, A. (2014). Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Advanced Healthcare Materials, 3(3), 400-411. doi:10.1002/adhm.201300280
Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions
Liptrott, N., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2014). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. Nanomedicine (London).
Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine
Curley, P., Liptrott, N., Tatham, L., Siccardi, M., & Owen, A. (2014). Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine. Poster session presented at the meeting of 7th CLINAM Conference and Exhibition. Basel, Switzerland.
Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'
Liptrott, N. J., Kendall, E., Nieves, D. J., Farrell, J., Rannard, S., Fernig, D. G., & Owen, A. (2014). Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'. Nanomedicine (London).
The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents
Curley, P., Giardiello, M., Liptrott, N., Martin, P., McDonald, T., Siccardi, M., . . . Owen, A. (2014). The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.
2013
Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation
Liptrott, N. J., Curley, P., Moss, D., Back, D. J., Khoo, S. H., & Owen, A. (2013). Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(11), 2545-2549. doi:10.1093/jac/dkt225
Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>
Moss, D. M., Liptrott, N. J., Curley, P., Siccardi, M., Back, D. J., & Owen, A. (2013). Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5612-5618. doi:10.1128/AAC.01421-13
High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against <i>Escherichia coli</i>
McDonald, T. O., Tatham, L. M., Southworth, F. Y., Giardiello, M., Martin, P., Liptrott, N. J., . . . Rannard, S. P. (2013). High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against <i>Escherichia coli</i>. JOURNAL OF MATERIALS CHEMISTRY B, 1(35), 4455-4465. doi:10.1039/c3tb20543f
Immunological Safety Assessment and Viral Efficacy of Novel Pickering Stabilised Nanoemulsions Containing Lopinavir and Efavirenz
Hobson, J. J., Liptrott, N., Martin, P., Ford, J., Slater, R., Rannard, S., & Owen, A. (2013, June 23). Immunological Safety Assessment and Viral Efficacy of Novel Pickering Stabilised Nanoemulsions Containing Lopinavir and Efavirenz. In Clinical Nanomedicine and Targeted Medicine. Basel, Switzerland.
ENHANCED PHARMACOLOGICAL PROPERTIES OF EFAVIRENZ FORMULATED AS SOLID DRUG NANOPARTICLES
Martin, P., Liptrott, N. J., McDonald, T., Giardiello, M., Roberts, P., Curley, P., . . . Owen, A. (2013). ENHANCED PHARMACOLOGICAL PROPERTIES OF EFAVIRENZ FORMULATED AS SOLID DRUG NANOPARTICLES. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta.
Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles
Martin, P., Liptrott, N., McDonald, T., Giardiello, M., Roberts, P., Curley, P., . . . Owen, A. (2013). Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli
McDonald, T. O., Tatham, L. M., Southworth, F. Y., Giardiello, M., Martin, P., Liptrott, N. J., . . . Rannard, S. P. (2013). High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli. Journal of Materials Chemistry B, 1(35), 4455. doi:10.1039/c3tb20543f
Nanomedicines for HIV Therapy
Siccardi, M., Martin, P., McDonald, T. O., Liptrott, N. J., Giardiello, M., Rannard, S., & Owen, A. (2013). Nanomedicines for HIV Therapy. Therapeutic Delivery, 4(2), 149-152.
Nanomedicines for HIV therapy.
Siccardi, M., Martin, P., McDonald, T. O., Liptrott, N. J., Giardiello, M., Rannard, S., & Owen, A. (2013). Nanomedicines for HIV therapy.. Therapeutic delivery, 4(2), 153-156. doi:10.4155/tde.12.156
Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system
Curley, P., Martin, P., Liptrott, N., Back, D., Owen, A., & Siccardi, M. (2013). Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.
2012
Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS
Liptrott, N. J., Pushpakom, S., Wyen, C., Faetkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. PHARMACOGENETICS AND GENOMICS, 22(1), 10-19. doi:10.1097/FPC.0b013e32834dd82e
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS
Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/fpc.0b013e32834dd82e
UPTAKE OF ANTIRETROVIRAL BASED SOLID DRUG NANOPARTICLES IN PRIMARY MONOCYTE DERIVED MACROPHAGES AND THEIR IMPACT ON MACROPHAGE FUNCTION
Liptrott, N. J., Martin, P., Giardiello, M., McDonald, T., Rannard, S. P., & Owen, A. (2012). UPTAKE OF ANTIRETROVIRAL BASED SOLID DRUG NANOPARTICLES IN PRIMARY MONOCYTE DERIVED MACROPHAGES AND THEIR IMPACT ON MACROPHAGE FUNCTION. In British Pharmacological Society Winter Meeting. London.
2011
IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV plus Patients
Liptrott, N. J., Egan, D., Back, D. J., & Owen, A. (2011). IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV plus Patients. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(5), 442-445. doi:10.1097/QAI.0b013e318236441c
Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), 450-457. doi:10.1097/qai.0b013e3182364c67
Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(5), 450-457. doi:10.1097/QAI.0b013e3182364c67
Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction
Pushpakom, S. P., Liptrott, N. J., Rodriguez-Novoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. JOURNAL OF INFECTIOUS DISEASES, 204(1), 145-153. doi:10.1093/infdis/jir215
Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction
Pushpakom, S. P., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. The Journal of Infectious Diseases, 204(1), 145-153. doi:10.1093/infdis/jir215
Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology
Watson, V., Liptrott, N., Egan, D., Dickinson, L., Tjia, J., Reynolds, H., . . . Back, D. (2011). Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Poster session presented at the meeting of 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA.
The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?
Liptrott, N. J., & Owen, A. (2011). The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 7(3), 341-352. doi:10.1517/17425255.2011.553600
Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2011). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(2), 879-887. doi:10.1128/AAC.00623-10
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction
Pushpakom, S. P., Liptrott, N. J., Rodriguez-Novoa, S., Labarga, P., Soriano, V., Albalater, M., & al, E. (2011). Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. The Journal of Infectious diseases.
Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients
Molto, J., Valle, M., Back, D., Cedeno, S., Watson, V., Liptrott, N., . . . Clotet, B. (2011). Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(1), 72-75. doi:10.1128/AAC.00789-10
The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?
Liptrott, N. J., & Owen, A. (2011). The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. Expert Opinion on Drug Metabolism and Toxicology.
2010
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms
Hartkoorn, R. C., San Kwan, W., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms. PHARMACOGENETICS AND GENOMICS, 20(2), 112-120. doi:10.1097/FPC.0b013e328335b02d
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics, 20(2), 112-120. doi:10.1097/fpc.0b013e328335b02d
ASSOCIATION OF ABCC10 POLYMORPHISMS WITH NEVIRAPINE PLASMA CONCENTRATIONS IN THE GERMAN COMPETENCE NETWORK FOR HIV/AIDS
Liptrott, N. J., Pushpakom, S., Wyen, C., Rockstroh, J., Mauss, S., Knechten, H., . . . German Competence Network for HIV/AIDS. (2010). ASSOCIATION OF ABCC10 POLYMORPHISMS WITH NEVIRAPINE PLASMA CONCENTRATIONS IN THE GERMAN COMPETENCE NETWORK FOR HIV/AIDS. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco.
Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS
Liptrott, N. J., Pushpakom, S., Wyen, C., Rockstroh, J., Mauss, S., Knechten, H., . . . Owen, A. (2010). Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 286). San Francisco: Conference on Retroviruses and Opportunistic Infections.
GENETIC VARIANTS OF ABCC10 ARE ASSOCIATED WITH KIDNEY TUBULAR DYSFUNCTION IN PATIENTS TREATED WITH TENOFOVIR-CONTAINING REGIMENS
Pushpakom, S., Liptrott, N. J., RodrÃguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2010). GENETIC VARIANTS OF ABCC10 ARE ASSOCIATED WITH KIDNEY TUBULAR DYSFUNCTION IN PATIENTS TREATED WITH TENOFOVIR-CONTAINING REGIMENS. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco.
Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens
Pushpakom, S., Liptrott, N. J., RodrÃguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2010). Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 352). San Francisco: Conference on Retroviruses and Opportunistic Infections.
RALTEGRAVIR IS A SUBSTRATE FOR THE INFLUX TRANSPORTERS OAT1 AND PEPT1 AND THE EFFLUX TRANSPORTER PGP, BUT IS NOT TRANSPORTED BY OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, OR PEPT2
Moss, D., Kwan, W. -S., Liptrott, N. J., Siccardi, M., Anstee, D., Khoo, S., . . . Owen, A. (2010). RALTEGRAVIR IS A SUBSTRATE FOR THE INFLUX TRANSPORTERS OAT1 AND PEPT1 AND THE EFFLUX TRANSPORTER PGP, BUT IS NOT TRANSPORTED BY OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, OR PEPT2. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco.
Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2
Moss, D., Kwan, W., Liptrott, N., Siccardi, M., Anstee, D., Khoo, S., . . . Owen, A. (2010). Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 293). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother, 55(2), 879-887.
2009
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. British Journal of Pharmacology, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.x
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. BRITISH JOURNAL OF PHARMACOLOGY, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.x
EVALUATING THE EFFECT OF GENDER ON DARUNAVIR AND RITONAVIR EXPOSURE IN HIV INFECTED SUBJECTS (A POST-HOC ANALYSIS OF THE GRACE PK SUB-STUDY)
Else, L., Liptrott, N. J., Moss, D., Dutton, J., Fraser, W., Kakude, T., . . . Back, D. (2009). EVALUATING THE EFFECT OF GENDER ON DARUNAVIR AND RITONAVIR EXPOSURE IN HIV INFECTED SUBJECTS (A POST-HOC ANALYSIS OF THE GRACE PK SUB-STUDY). In 11th International Workshop on Clinical Pharmacology of HIV Therapy. Sorrento.
Pharmacological and Immunological factors that influence Antiretroviral Drug Response
Liptrott, N. J. (2009). Pharmacological and Immunological factors that influence Antiretroviral Drug Response. (PhD Thesis, The University of Liverpool).
2008
Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry
Liprott, N. J., Khoo, S. H., Back, D. J., & Owen, A. (2008). Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. JOURNAL OF IMMUNOLOGICAL METHODS, 339(2), 270-274. doi:10.1016/j.jim.2008.09.010
INTERFERON GAMMA GENOTYPE (874T>A) IS ASSOCIATED WITH CCR5 EXPRESSION IN HIV+ PATIENTS
Liptrott, N. J., Chandler, R., Khoo, S. H., Back, D. J., & Owen, A. (2008). INTERFERON GAMMA GENOTYPE (874T>A) IS ASSOCIATED WITH CCR5 EXPRESSION IN HIV+ PATIENTS. In 15th Conference on Retroviruses and Opportunistic Infections. Boston.
2007
INFLUENCE OF PD-1 GENOTYPE ON VIROLOGICAL AND IMMUNOLOGICAL RESPONSE IN PATIENTS INITIATING HAART
Liptrott, N. J., Mahungu, T., Youle, M., Johnson, M., Smith, C., Khoo, S. H., . . . Owen, A. (2007). INFLUENCE OF PD-1 GENOTYPE ON VIROLOGICAL AND IMMUNOLOGICAL RESPONSE IN PATIENTS INITIATING HAART. In 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles.
2006
RELATIONSHIP OF G516T POLYMORPHISM TO LYMPHOCYTE EXPRESSION OF CYP2B6
Owen, A., Cook, C., Liptrott, N. J., Khoo, S., & Back, D. (2006). RELATIONSHIP OF G516T POLYMORPHISM TO LYMPHOCYTE EXPRESSION OF CYP2B6. In 13th Conference on Retroviruses and Opportunistic Infections. Denver.
The impact of cytokines on the expression of HIV-relevant, membrane-bound proteins
Liptrott, N., Back, D. J., Khoo, S. H., Penny, M., & Owen, A. (2006). The impact of cytokines on the expression of HIV-relevant, membrane-bound proteins. In DRUG METABOLISM REVIEWS Vol. 38 (pp. 124-125). Retrieved from https://www.webofscience.com/
Undated
Developing safer HIV drugs: elucidating the mechanistic pathway of Tenofovir-induced cytotoxicity via mitochondrial dysfunction
Mellor, C. (n.d.). Developing safer HIV drugs: elucidating the mechanistic pathway of Tenofovir-induced cytotoxicity via mitochondrial dysfunction. (PhD Thesis, University of Liverpool).